Thomas Eissing

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Clinical Decision Support

Chronic Kidney Disease

Epidermal Growth Factor Receptor

Top Venues

Clinical pharmacokinetics

Clinical journal of the American Society of Nephrology : CJASN

CPT: pharmacometrics & systems pharmacology

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Caroline A Gluck, Christopher B Forrest, Amy Goodwin Davies, Mitchell Maltenfort, Jill R Mcdonald, Mark M Mitsnefes, Vikas R Dharnidharka, Bradley P Dixon, Joseph T Flynn, Michael J Somers, William E Smoyer, Alicia Neu, Collin A Hovinga, Amy L Skversky, Thomas Eissing, Andreas Kaiser, Stefanie Breitenstein, Susan L Furth, Michelle R Denburg
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database. Clinical journal of the American Society of Nephrology : CJASN 18 (2) (2023)
Caroline A Gluck, Christopher B Forrest, Amy Goodwin Davies, Mitchell Maltenfort, Jill R Mcdonald, Mark M Mitsnefes, Vikas R Dharnidharka, Bradley P Dixon, Joseph T Flynn, Michael J Somers, William E Smoyer, Alicia Neu, Collin A Hovinga, Amy L Skversky, Thomas Eissing, Andreas Kaiser, Stefanie Breitenstein, Susan L Furth, Michelle R Denburg
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database. Clinical journal of the American Society of Nephrology : CJASN 18 (2) (2023)
Thomas Eissing, Sebastiaan Camiel Goulooze, Paul van den Berg, Martijn van Noort, Martijn Ruppert, Martijn van Noort, Dirk Garmann, Joerg Lippert, Roland Heinig, Meike Brinker, Hiddo J Lambers Heerspink
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, obesity & metabolism (2023)
Roland Heinig, Thomas Eissing
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. Clinical pharmacokinetics (2023)
Caroline A Gluck, Christopher B Forrest, Amy Goodwin Davies, Mitchell Maltenfort, Jill R Mcdonald, Mark M Mitsnefes, Vikas R Dharnidharka, Bradley P Dixon, Joseph T Flynn, Michael J Somers, William E Smoyer, Alicia Neu, Collin A Hovinga, Amy L Skversky, Thomas Eissing, Andreas Kaiser, Stefanie Breitenstein, Susan L Furth, Michelle R Denburg
Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database. Clinical journal of the American Society of Nephrology : CJASN 18 (2) (2023)
Sebastiaan Camiel Goulooze, Hiddo J Lambers Heerspink, Martijn van Noort, Nelleke Snelder, Meike Brinker, Joerg Lippert, Thomas Eissing
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. Clinical pharmacokinetics 61 (7) (2022)
Thomas Wendl, Sebastian Frechen, Michael Gerisch, Roland Heinig, Thomas Eissing
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. CPT: pharmacometrics & systems pharmacology (2021)
Paul van den Berg, Martijn Ruppert, Emir Mesic, Nelleke Snelder, Andreas Seelmann, Roland Heinig, Amer Joseph, Dirk Garmann, Joerg Lippert, Thomas Eissing
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clinical pharmacokinetics (2021)
Sebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, Andrea Horvat-Broecker, Meike Brinker, Amer Joseph, Dirk Garmann, Joerg Lippert, Thomas Eissing
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clinical pharmacokinetics (2021)